drugset / Trial / NCT00161798

Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.

NCT00161798 ↗

Phase 2 Completed Pfizer
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to investigate the safety and immunogenicity of three different concentrations of a TBE vaccine will be investigated in healthy children aged 6 to 16 years.

Timeline

Start
2001-09
Primary completion
—
Completion
2002-03

Drugs

EvaluationDrugModalityDoseRoute
Subject FSME IMMUN NEW Vaccine — —